Essiac (ESIAK) Versus Placebo to Improve Quality of Life in Transition in Women With Breast or Ovarian Cancer.
Status:
Terminated
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
This is a pilot feasibility study being performed in women completing front-line treatment
for breast or ovarian cancer. It is being done to evaluate whether or not an herbal
combination known as Essiac (ESIAK) can improve the overall quality of life in these women as
they transition from active treatment to follow-up, also known as the quality of life in
transition. This information will be used to design a larger randomized trial.